De Novo device
Eroxon
Futura Medical Developments Limited · Non-Medicated Topical Formulation For Treatment Of Erectile Dysfunction. (QWW, Class II) · First FDA decision Jun 9, 2023, newest Jun 9, 2023Erectile dysfunction
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
De Novo pathway
Device trials
1
Naming "Eroxon"
MAUDE reports
3
Brand "Eroxon", since 2015
PubMed studies
4
Mentioning "Eroxon"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Eroxon
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- EroxonNew device typeDe Novo
DEN220078 · Decided Jun 9, 2023 · 231 days after receipt
Device type: Non-Medicated Topical Formulation For Treatment Of Erectile Dysfunction. (QWW) · GI, Urology & Nephrology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Eroxon", any status and sponsor, newest update first.
University of MiamiAcademic, hospital or other
NCT07636161 · 30 participants (planned) · Start Oct 2026 · Primary completion Sep 2027
Device: Eroxon® · For: Type 2 Diabetes; Type 2 Diabetes (T2DM)
Sites: Miami, Florida
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Eroxon", and for the whole product code for context.
This brand
3 reports: 1 malfunction, 2 injury, 0 death
Whole product code QWW
1 reports: 1 malfunction, 0 injury, 0 death
Newest reports for this brand
- EROXON FAST ACTINGInjury
3012293198-2025-00134 · Received Apr 18, 2025
Device type: Saliva, Artificial (LFD)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Paresthesia; Erectile Dysfunction; Appropriate Clinical Signs, Symptoms and Conditions Term/Code Not Available
- EROXON FAST ACTINGInjury
3012293198-2025-00064 · Received Mar 20, 2025
Device type: Saliva, Artificial (LFD)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Eye Infections; Appropriate Clinical Signs, Symptoms and Conditions Term/Code Not Available
- EROXONMalfunction
FUTURE MEDICAL IN BRITAIN UK/FUTURA MEDICAL DEVELOPMENTS LIMITED
MW5162399 · Received Nov 8, 2024
Device type: Non-Medicated Topical Formulation For Treatment Of Erectile Dysfunction. (QWW)
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Eroxon"[tiab]. The summary above synthesizes these.
- Unmet needs in the treatment of erectile dysfunction and a place for topical treatments in the therapeutic landscape.
Brock GB, Yafi FA, Hellstrom WJG, et al. · J Sex Med · 2026Research Support, Non-U.S. Gov't
- Eroxon - an OTC gel for erectile dysfunction.
Med Lett Drugs Ther · 2024
- Efficacy and Safety of MED2005, a Topical Glyceryl Trinitrate Formulation, in the Treatment of Erectile Dysfunction: A Randomized Crossover Study.
Ralph DJ, Eardley I, Taubel J, et al. · J Sex Med · 2018Clinical Trial, Phase II, Randomized Controlled Trial
- In brief: Vybrique - sildenafil oral film for erectile dysfunction.
Med Lett Drugs Ther · 2026
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.